1) p210bcr/abl protein
p210ber/abl蛋白
2) Bcr-Abl protein
Bcr-Abl蛋白
1.
Methods The amounts of Bcr-Abl protein were tested by Western blot.
结果NB能降低HL-60/Bcr-Abl细胞中Bcr-Abl的蛋白水平,NB使Bcr-Abl与Hsp90和Hsp70的结合减少,促进蛋白酶体降解Bcr-Abl蛋白,ALLnL处理后NP-40insoluble部分Bcr-Abl蛋白水平提高。
2.
Aim To confirm the effects of Hsp90 inhibitor NB on STI571 resistant K562/G01 cells,and reveal the effect of combination of NB and STI571 on STI571 sensitive or resistant cells;to further clarify the relationship between growth inhibition and Bcr-Abl protein level and its kinase activity.
目的研究热休克蛋白90(Hsp90)抑制剂新生霉素(novobiocin,NB)对STI571耐药K562/G01细胞生长的抑制作用,并研究NB和STI571联合应用对STI571敏感和耐药细胞的作用,并进一步探讨该作用与Bcr-Abl蛋白水平和Bcr-Abl激酶水平的关系。
3) Bcr-Abl
Bcr-Abl蛋白
1.
Inhibition of Novobiocin on Proliferation of Bcr-Abl-positive Human Leukemia Cells Involves Disruption Chaperon Function of Hsp90;
Bcr-Abl蛋白是由bcr/abl融合基因编码的,具有比正常的p145c-abl激酶更强的酪氨酸激酶活性,是慢性粒细胞白血病(CML)对抗化疗药物诱导凋亡的。
4) p210 bcr/abl protein
p210 bcr/abl蛋白
1.
Methods Human Ph + CML leukemia K562 cells, which express endogenous p210 bcr/abl protein, were cultured in RPMI 1640 and treated with berbamine as indicated time and dose.
方法培养表达内源性p210 bcr／abl蛋白的Ph+人慢性粒细胞白血病细胞系K562,用小檗胺按指定时间和剂量干预细胞。
5) BCR-ABL fusion protein
BCR-ABL融合蛋白
1.
To predict B cell epitope for the fusion region of BCR-ABL fusion protein(p210~(BCR-ABL))in chronic myeloid leukemia,based on BCR-ABL fusion protein sequence,the B cell epitope for BCR-ABL fusion region was predicted by methods of EMBOSS program,DNAstar software,hopp and woods hydrophility,Janin accessibility,polarity,flexibility and secondary structure.
以BCR-ABL融合蛋白氨基酸序列为基础,采用EMBOSS软件及DNAstar软件结合Hopp and Woods亲水性参数、Janin可及性参数、极性参数、柔韧性参数及二级结构方案对慢性粒细胞白血病BCR-ABL融合蛋白(p210~(BCR-ABL))融合区的B细胞表位进行预测。
6) P210~ bcr/abl fusion protein
P210bcr/abl融合蛋白
1.
This study was aimed to explore the expression of MIP-1α,MCP-1 and their receptors CCR-1, CCR-2 in bcr/abl fusion gene positive CML cells, and to study the effects of P210~ bcr/abl fusion protein tyrosine kinase on expression of MIP-1α, MCP-1 and their receptors CCR-1, CCR-2 mRNAs in chronic myeloid leukemia cells.
本文旨在研究MIP-1α和MCP-1及其受体CCR-1和CCR-2在慢性髓系白血病细胞中的表达,同时观察P210bcr/abl融合蛋白中酪氨酸激酶对MIP-1α和MCP-1及其受体CCR-1和CCR-2mRNA表达的影响。
补充资料：钋-210(polonium-210)
【钋-210】(polonium-210)俗称“镭F（RaF）”。质量数为210的钋的天然放射性核素。半衰期138.4天。发射`\alpha`辐射。可从阵氡管中提取。与轻元素铍均匀混合紧密压制可制成钋-铍中子源。用于油井测井及实验室研究，也可用作`\alpha`射线标准源。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条